Politics Wins Out Over Science In Congressional Debates

WASHINGTON--Senators and representatives return next week from their annual August recess knowing that they still face many important issues. But what to do about big science should not be one of them. That debate appears to have been settled, at least for this year. A series of votes this summer attempted to establish an acceptable balance between funding huge teams of scientists working on multibillion-dollar construction projects and continuing to nurture individual investigators engaged in

Written byJeffrey Mervis
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

That debate appears to have been settled, at least for this year. A series of votes this summer attempted to establish an acceptable balance between funding huge teams of scientists working on multibillion-dollar construction projects and continuing to nurture individual investigators engaged in small-scale science.

The results of the debate favored size: A bill to double the superconducting supercollider's budget for the 1992 fiscal year was signed by the president last month. Both the Senate and the House have separately approved a $2 billion appropriation for the space station, although differences in the two measures must still be worked out.

Those projects won out despite fervent efforts by several professional societies and individual scientists to limit big science's rate of growth, arguing that the megaprojects were robbing the little guys.

What part have scientific issues played in all of this? Not a starring role: Other considerations took precedence as the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies